Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/25/2026, 12:00:00 AM
Announced an exclusive license agreement with Alteogen on March 25, 2026, to develop subcutaneous formulations for two products. The deal includes a $20 million upfront payment and up to $549 million in potential milestones plus royalties. This event is estimated to have a low impact given the relatively small upfront payment.
Korean Translation
2026년 3월 25일, 알테오젠과 2개 제품에 대한 피하 제형 개발을 위한 독점 라이선스 계약을 발표함. 계약금 2,000만 달러와 최대 5억 4,900만 달러의 마일스톤 및 로열티를 포함함. 계약금 규모가 작아 낮은 영향이 예상됨.
Related Recent Events
Novo Nordisk A/S (NVO) · Other
Announced on Feb 24, 2026, that it will lower the U.S. list prices of key drugs Wegovy and Ozempic by approximately 50% and 35% respectively, effective January 1, 2027, to improve patient access.
1/1/2027, 12:00:00 AM
Novartis AG (NVS) · Other
Results from the Phase III Lp(a)HORIZON study of cardiovascular candidate pelacarsen are scheduled for 2026-06-30; this key clinical readout is estimated to have a >5% price impact expected.
6/30/2026, 12:00:00 AM
RELX PLC (RELX) · Other
Ex-dividend date for the 48.0 pence per share final dividend for fiscal year 2025 on May 7, 2026; dividend-related price adjustments are typically low, scheduled
5/7/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Earnings Release
First quarter 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Leidos Holdings Inc (LDOS) · Earnings Release
Leidos is scheduled to release Q1 2026 financial results on May 5, 2026, with analysts forecasting EPS of $2.91-$2.94 expected.
5/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer's Q1 2026 earnings release is scheduled for May 5, 2026, scheduled.
5/5/2026, 12:00:00 AM